0001209191-21-037615.txt : 20210603 0001209191-21-037615.hdr.sgml : 20210603 20210603160727 ACCESSION NUMBER: 0001209191-21-037615 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210601 FILED AS OF DATE: 20210603 DATE AS OF CHANGE: 20210603 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Dube Eric M CENTRAL INDEX KEY: 0001763494 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36257 FILM NUMBER: 21992561 MAIL ADDRESS: STREET 1: 3721 VALLEY CENTRE DRIVE, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Travere Therapeutics, Inc. CENTRAL INDEX KEY: 0001438533 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 262383102 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3611 VALLEY CENTRE DR STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 888-969-7879 MAIL ADDRESS: STREET 1: 3611 VALLEY CENTRE DR STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: Retrophin, Inc. DATE OF NAME CHANGE: 20130220 FORMER COMPANY: FORMER CONFORMED NAME: Desert Gateway, Inc. DATE OF NAME CHANGE: 20080625 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-06-01 0 0001438533 Travere Therapeutics, Inc. TVTX 0001763494 Dube Eric M C/O TRAVERE THERAPEUTICS, INC. 3611 VALLEY CENTRE DR., SUITE 300 SAN DIEGO CA 92130 1 1 0 0 Chief Executive Officer Common Stock 2021-06-01 4 S 0 4782 14.89 D 152031 D Common Stock 2021-06-02 4 S 0 4780 14.35 D 147251 D The sales reported were made pursuant to a written plan adopted on June 15, 2020 and meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. /s/ Elizabeth E. Reed, Attorney-in-Fact 2021-06-03